Phase 2 N=24 Gut Decontamination In Pediatric Allogeneic Hematopoietic
Hematopoietic Stem Cell Transplantation (HSCT) · Acute GVH Disease
Primary: Gut Microbiome Description — 2.4; 3.1 Shannon diversity index
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis
Brain Metastasis
Primary: Number of Participants With Symptomatic Radiation Necrosis — 1 Participants
Phase 2 N=81 Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
COVID-19
Primary: Change in Oxygenation — 56.4; 20.6; 123.5; 83.7 mmHg
Phase 2 N=20 Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Prostate Cancer
Primary: Phase Ib: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0 percentage of participants
Phase 2 N=53 A Novel Human Lab Model for Screening AUD Medications
Alcohol Use Disorder
Primary: Percentage of Days Abstinent — 80.59; 75.62; 77.59 percent days
Phase 2 N=89 Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Breast Cancer
Primary: Phase 1b: Participants Experiencing DLT — 0 Participants
Phase 2 N=19 Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
Pyoderma Gangrenosum
Primary: Treatment-emergent Adverse Events (TEAEs), Related TEAEs, Serious TEAEs, and Adverse Events of Special Interest (AESIs) — 6; 4; 5; 0 Participants
Phase 2 N=127 A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member · Acute Myelogenous Leukemia · Acute Lymphoblastic Leukemia
Primary: Percentage of Donors Whose Cells Were Successfully Mobilized and Collected With a Sufficient CD34+ Cell Dose Using Plerixafor as the Mobilizing Agent, Using an…
Phase 2 N=18 Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
Diffuse Large B Cell Lymphoma
Primary: Stage I - Safety (Type, Frequency, Severity and Relationship of Adverse Events to Study Treatment) and Tolerability — 25 mg
Phase 2 N=75 A Study In Adults With Moderate To Severe Dermatomyositis
Dermatomyositis
Primary: Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) — -3.44…
Phase 2 N=15 Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag
Anemia, Diamond-Blackfan
Primary: Participants That Responded to Eltrombopag — 1; 14 Participants
Phase 2 N=20 IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3
Small Fiber Neuropathy · Idiopathic Peripheral Neuropathy
Primary: The Change in Nerve Fiber Density Between Visits 1 and 8. — 0.5; 0.6 fibers/mm
Phase 2 N=272 A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Obesity · Overweight and Obesity
Primary: Percent Change From Baseline in Body Weight in LY3502970 and Placebo — -8.6; -11.2; -12.3; -12.6 Percent change — p=<0.001
Phase 2 N=338 A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
Obesity · Overweight
Primary: Mean Percent Change From Baseline in Body Weight — -1.55; -7.18; -12.00; -13.80 percent change — p=<0.001
Phase 2 N=9 Imaging Inflammation in Alzheimer's Disease With 11C-ER176
Alzheimer Disease
Primary: 11C-ER176 Total Distribution Volume — 6.27; 9.32 mL/cm^3